Whole-Body Physiologically Based Pharmacokinetic Modeling of Trastuzumab and Prediction of Human Pharmacokinetics. 2019

Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
ASAN Institute for Life Sciences, ASAN Medical Center, Seoul, Republic of Korea.

In the present study, we evaluated the pharmacokinetics (PK) of trastuzumab and sought to predict human PK based on animal studies, through the use of optical imaging and a whole-body physiologically based pharmacokinetic (WB-PBPK) modeling approach. The PK study was conducted in 24 mice, where serial blood samples were withdrawn and major organs were isolated after the last blood withdrawal. The drug concentrations in blood and major organs were measured via optical imaging. The WB-PBPK model was constructed using known physiological values including the volumes of major organs and blood/lymphatic flow. The NONMEM software (version 7.3) was used to determine tissue partition coefficients. Using the WB-PBPK model, a clinical trial simulation was performed with reference to human physiological values acquired from the literature. The simulated human PK was then compared with the actual PK observed in the previous study in which healthy male subjects received 6 mg/kg trastuzumab (Herceptin®) via intravenous route. The ratio of the simulated versus observed area under the concentration-time curve was 1.02 and that of maximal concentration was 0.72. The current study describes the potential synergistic applications of WB-PBPK and optical imaging in human PK prediction based on preclinical data obtained in early-stage drug development.

UI MeSH Term Description Entries
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068878 Trastuzumab A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed. Trastuzumab beta,Trastuzumab-qyyp,Trazimera,Herceptin,Trastuzumab qyyp,beta, Trastuzumab
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions

Related Publications

Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
January 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
December 2010, Journal of nanoscience and nanotechnology,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
April 2007, Expert opinion on drug metabolism & toxicology,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
February 2019, European journal of drug metabolism and pharmacokinetics,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
March 2021, Journal of clinical medicine,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
April 2020, Biopharmaceutics & drug disposition,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
December 2019, CPT: pharmacometrics & systems pharmacology,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
August 2018, Journal of theoretical biology,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
November 2020, Clinical pharmacokinetics,
Dong-Jun Bae, and Sang-Yeob Kim, and Sang Mun Bae, and Ae-Kyung Hwang, and Kwan Cheol Pak, and SeokKyu Yoon, and Hyeong-Seok Lim
February 1998, Journal of pharmacokinetics and biopharmaceutics,
Copied contents to your clipboard!